Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.40 – $4.00
10% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $529.1M | $524.0M | $456.6M | $400.3M | $157.1M | $183.6M | $388.2M | $408.1M |
| Cost of revenue | $266.3M | $222.6M | $231.5M | $205.6M | $253.8M | $156.7M | $169.6M | $160.8M |
| Gross profit | $262.9M | $301.4M | $225.1M | $194.7M | $170.1M | $26.8M | $218.5M | $247.3M |
| Gross margin | 49.7% | 57.5% | 49.3% | 48.6% | 108.3% | 14.6% | 56.3% | 60.6% |
| R&D | $12.3M | $25.8M | $24.8M | $45.8M | $25.3M | $15.7M | $21.6M | $19.5M |
| Operating income | $40.7M | $15.4M | $3.5M | −$36.5M | −$135.6M | −$186.4M | −$139.1M | −$23.6M |
| EBITDA | $120.5M | $109.9M | $88.1M | $50.0M | −$46.3M | −$174.4M | −$87.1M | $42.1M |
| Net income | −$134.0M | −$280.9M | −$92.8M | −$208.4M | −$209.5M | $117.2M | −$174.2M | −$93.8M |
| Net margin | -25.3% | -53.6% | -20.3% | -52.1% | -133.3% | 63.9% | -44.9% | -23.0% |
| EPS (diluted) | -1.83 | -3.81 | -1.21 | -2.65 | -3.20 | -3.67 | -2.12 | -1.14 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $403M | $-0.43 | $-0.43–$-0.43 | 1 |
| 2027 | $405M | $-0.44 | $-0.44–$-0.44 | 1 |
| 2028 | $419M | $-0.32 | $-0.32–$-0.32 | 1 |
Forward consensus · source: Financial Modeling Prep
MAYNE PHARMA GROUP LTD
No one on the platform currently holds MAYNF.
No tracked institution reports a position in MAYNF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-01-18 | 1-for-20reverse |
No one on the platform has traded MAYNF yet.
| +1.93% |
| $295M |
| — |
| EVGRFChina Evergrande New Energy Vehicle Group Limited | $0.00 | +0.00% | $2M | — |
| HNSBFHansa Biopharma AB | $2.90 | +0.00% | $246M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.2× sales vs its 1.0× historical median P/S.
Fair value ≈ $6.92 · price $1.65 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.